13F Holdings
中文EN

IONS IONIS PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 874015 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.7%
TTM net income YoY-113.2%
TTM EPS YoY-96.4%
Revenue 3-yr CAGR16.0%
Net income 3-yr CAGR—

Margins

Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
FCF margin-64.2%
EBITDA margin-57.4%

Returns

ROE-108.1%
ROA-18.4%
ROIC (approx.)-236.8%
Asset turnover0.32x

Leverage & solvency

Liabilities / assets86.5%
Debt / equity0.00x
Current ratio5.43x
Interest coverage-29.37x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue7.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$943.71M$705.14M$787.65M$587.37M$810.46M
Cost of revenue$15.91M$11.21M$9.13M$14.12M$10.84M
Gross profit$927.80M$693.92M$778.51M$573.25M$799.61M
R&D expense$915.62M$901.53M$899.62M—$638.20M
SG&A expense$393.87M$267.47M$232.62M$150.29M$186.35M
Operating income-$381.68M-$475.08M-$353.73M-$410.19M-$30.19M
Interest expense$17.26M$16.99M$12.66M$8.12M$9.35M
Pretax income-$379.60M-$460.07M-$333.96M-$257.99M-$29.15M
Income tax$1.79M-$6.17M$32.32M$11.74M-$551,000
Net income-$381.39M-$453.90M-$366.29M-$269.72M-$28.60M
EBITDA-$371.68M-$465.47M-$343.44M-$395.86M-$14.70M
EPS (basic)-2.38-3.04-2.56-1.90-0.20
EPS (diluted)-2.38-3.04-2.56-1.90-0.20
Weighted avg. shares (diluted)160.01M149.51M143.19M141.85M141.02M
Balance sheet
Cash & equivalents$372.26M$242.08M$399.27M$276.47M$869.19M
Short-term investments$2.31B$2.06B$1.93B$1.71B$1.25B
Inventory$10.05M$12.51M$7.44M$22.03M$24.81M
Current assets$2.99B$2.62B$2.64B$2.20B$2.35B
PP&E, net$123.05M$94.25M$71.04M$74.29M$178.07M
Intangibles————$29.00M
Total assets$3.52B$3.00B$2.99B$2.53B$2.61B
Current liabilities$781.57M$309.32M$448.09M$311.56M$240.55M
Short-term debt$432.12M$165,000$157,000$151,000—
Long-term debt$1.33B$1.20B$1.24B$1.18B—
Total debt$1.76B$1.20B$1.24B$1.18B—
Total liabilities$3.03B$2.42B$2.60B$1.96B$1.84B
Shareholders' equity$489.09M$588.35M$386.69M$572.89M$771.74M
Net debt$1.39B$960.49M$841.89M$899.40M—
Shares outstanding163.30M157.91M144.34M142.06M141.21M
Cash flow statement
Operating cash flow-$268.58M-$500.95M-$307.51M-$274.37M$30.80M
Capital expenditure$51.44M$45.28M$23.80M$15.72M$11.96M
Free cash flow-$320.03M-$546.23M-$331.32M-$290.09M$18.84M
Investing cash flow-$277.78M-$134.03M-$214.13M-$262.64M$194.91M
Financing cash flow$675.84M$478.06M$644.08M-$55.30M$245.93M
Depreciation & amortization$10.01M$9.61M$10.29M$14.33M$15.49M
Stock-based compensation$133.87M$130.20M$105.81M$100.26M$120.68M
Share buybacks———$0$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.